# EDGAR Filing Document

**Accession Number:** 0000744825
**File Stem:** 0001437749-26-017046
**Filing Date:** 2026-5
**Character Count:** 130603
**Document Hash:** c3d1db7d928447af391418ff742e1855
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001437749-26-017046.hdr.sgml**: 20260514

**ACCESSION NUMBER**: 0001437749-26-017046

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 60

**CONFORMED PERIOD OF REPORT**: 20260331

**FILED AS OF DATE**: 20260514

**DATE AS OF CHANGE**: 20260514

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AMERICAN SHARED HOSPITAL SERVICES
- **CENTRAL INDEX KEY:** 0000744825
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MEDICAL LABORATORIES [8071]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 942918118
- **STATE OF INCORPORATION:** CA
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-08789
- **FILM NUMBER:** 26978854

**BUSINESS ADDRESS:**
- **STREET 1:** 601 MONTGOMERY STREET
- **STREET 2:** SUITE 1112
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111
- **BUSINESS PHONE:** 415-788-5300

**MAIL ADDRESS:**
- **STREET 1:** 601 MONTGOMERY STREET
- **STREET 2:** SUITE 1112
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94111

?xml version='1.0' encoding='ASCII'? asha20260331_10q.htm

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

------

**FORM 10-Q**

**(Mark One)**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2026 or**

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from _______________ to _______________.**

**Commission file number 001-08789**

------

**American Shared Hospital Services**

**(Exact name of registrant as specified in its charter)**

---

| | |
|:---|:---|
| **California** | **94-2918118** |
| **(State or other jurisdiction of**<br> **incorporation or organization)** | **(IRS Employer**<br> **Identification No.)** |

---

---

| | | | | |
|:---|:---|:---|:---|:---|
| **601 Montgomery Street** | **Suite 850** | **San Francisco,**  | **California** | **94111-2619** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip code)** |

---

**(415) 788-5300**

**(Registrant**'**s telephone number, including area code)** 

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| American Shared Hospital Services Common Stock, No Par Value | AMS | NYSE AMERICAN |

---

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large Accelerated Filer ☐ | Accelerated Filer ☐ | Non-Accelerated Filer ☒ | Smaller reporting company ☒ |
| Emerging Growth Company ☐ |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by a check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of May 11, 2026, there were outstanding 6,625,000 shares of the registrant's common stock.

------

**PART I** – **FINANCIAL INFORMATION**

**Item 1.**&nbsp;&nbsp;&nbsp;&nbsp;**Financial Statements**

**AMERICAN SHARED HOSPITAL SERVICES**

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

---

| | | |
|:---|:---|:---|
| **ASSETS** | ***March 31, 2026*** | ***December 31, 2025*** |
| Current assets: |  |  |
| Cash and cash equivalents | $4973000 | $3462000 |
| Restricted cash | 250000 | 250000 |
| Accounts receivable, net of allowance for credit losses of $980,000 and $980,000 at March 31, 2026 and December 31, 2025, respectively | 10566000 | 10521000 |
| Tax receivables | 569000 | 978000 |
| Other receivables | 467000 | 1021000 |
| &nbsp;&nbsp;&nbsp; VAT credits | 617000 | 702000 |
| Prepaid expenses and other current assets | 830000 | 786000 |
| **Total current assets** | **18272000** | **17720000** |
| Property and equipment, net | 29869000 | 31122000 |
| Land | 1305000 | 1305000 |
| Goodwill | 1265000 | 1265000 |
| Intangible asset | 78000 | 78000 |
| Right of use assets, net | 3610000 | 3648000 |
| Other assets | 326000 | 341000 |
| **Total assets** | $**54725000** | $**55479000** |
| **LIABILITIES AND SHAREHOLDERS' EQUITY** |  |  |
| Current liabilities: |  |  |
| Accounts payable | $1081000 | $607000 |
| Employee compensation and benefits | 1259000 | 1504000 |
| Other accrued liabilities | 1923000 | 1752000 |
| &nbsp;&nbsp;&nbsp; Related party liabilities | 1256000 | 937000 |
| Asset retirement obligations, related party (includes $250,000 and $250,000 non-related party at March 31, 2026 and December 31, 2025, respectively) | 1200000 | 1200000 |
| Current portion of lease liabilities | 156000 | 150000 |
| Current portion of long-term debt, net | 16843000 | 17294000 |
| **Total current liabilities** | **23718000** | **23444000** |
| Long-term lease liabilities, less current portion | 4187000 | 4229000 |
| Deferred income taxes | 115000 | 115000 |
| **Total liabilities** | **28020000** | **27788000** |
| Commitments (see Note 8) |  |  |
| Shareholders' equity: |  |  |
| Common stock, no par value (10,000,000 authorized shares; Issued and outstanding shares - 6,600,000 at March 31, 2026 and 6,575,000 at December 31, 2025) | 10763000 | 10763000 |
| Additional paid-in capital | 9110000 | 9009000 |
| Retained earnings | 3650000 | 4262000 |
| Total equity-American Shared Hospital Services | 23523000 | 24034000 |
| Non-controlling interests in subsidiaries | 3182000 | 3657000 |
| **Total shareholders' equity** | **26705000** | **27691000** |
| **Total liabilities and shareholders' equity** | $**54725000** | $**55479000** |

---

See accompanying notes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1

------

**AMERICAN SHARED HOSPITAL SERVICES**

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Revenues: |  |  |
| Rental revenue from medical equipment leasing | $3020000 | $2991000 |
| Direct patient services revenue | 4064000 | 3121000 |
|  | 7084000 | 6112000 |
| Costs of revenue: |  |  |
| Maintenance and supplies | 813000 | 610000 |
| Depreciation and amortization | 1289000 | 1445000 |
| Other direct operating costs | 3446000 | 2864000 |
| Other direct operating costs, related party | 248000 | 251000 |
|  | 5796000 | 5170000 |
| Gross margin | 1288000 | 942000 |
| Selling and administrative expense | 1910000 | 1808000 |
| Interest expense | 302000 | 433000 |
| Operating loss | (924000) | (1299000) |
| Interest and other income, net | 54000 | 64000 |
| Loss before income taxes | (870000) | (1235000) |
| Income tax expense (benefit) | 92000 | (323000) |
| Net loss | (962000) | (912000) |
| Less: net loss attributable to non-controlling interests | 350000 | 287000 |
| Net loss attributable to American Shared Hospital Services | $(612000) | $(625000) |
| Net loss per share: |  |  |
| Loss per common share - basic | $(0.09) | $(0.10) |
| Loss per common share - diluted | $(0.09) | $(0.10) |
| Weighted average common shares for basic loss per share | 6725000 | 6572000 |
| Weighted average common shares for diluted loss per share | 6725000 | 6572000 |

---

See accompanying notes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2

------

**AMERICAN SHARED HOSPITAL SERVICES**

CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY

(Unaudited)

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
|  | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* | *FOR THE THREE-MONTH PERIODS ENDED MARCH 31, 2026 AND 2025* |
|  | ***Common Shares*** | ***Common Stock*** | ***Additional Paid-in Capital*** | ***Retained Earnings*** | ***Sub-Total ASHS*** | ***Non-controlling Interests in Subsidiaries*** | ***Total*** |
| Balances at January 1, 2025 | 6420000 | $10763000 | $8605000 | $5815000 | $25183000 | $4844000 | $30027000 |
| Stock-based compensation expense | *-* |  | 89000 | *-* | 89000 | *-* | 89000 |
| Vested restricted stock awards | 30000 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Capital contributions from non-controlling interests | *-* |  |  |  |  | 8000 | 8000 |
| &nbsp;&nbsp;&nbsp; Net loss | *-* |  |  | (625000) | (625000) | (287000) | (912000) |
| Balances at March 31, 2025 | 6450000 | $10763000 | $8694000 | $5190000 | $24647000 | $4565000 | $29212000 |
| Balances at January 1, 2026 | 6575000 | $10763000 | $9009000 | $4262000 | $24034000 | $3657000 | $27691000 |
| &nbsp;&nbsp;&nbsp; Stock-based compensation expense | *-* |  | 101000 | *-* | 101000 | *-* | 101000 |
| &nbsp;&nbsp;&nbsp; Vested restricted stock awards | 25000 |  |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp; Cash distributions to non-controlling interests | *-* |  |  |  |  | (125000) | (125000) |
| &nbsp;&nbsp;&nbsp; Net loss | *-* |  |  | (612000) | (612000) | (350000) | (962000) |
| Balances at March 31, 2026 | 6600000 | $10763000 | $9110000 | $3650000 | $23523000 | $3182000 | $26705000 |

---

See accompanying notes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3

------

**AMERICAN SHARED HOSPITAL SERVICES**

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **Operating activities:** |  |  |
| Net loss | $(962000) | $(912000) |
| &nbsp;&nbsp;&nbsp; Adjustments to reconcile net loss to net cash from operating activities: |  |  |
| Depreciation, amortization, and other | 1294000 | 1449000 |
| &nbsp;&nbsp;&nbsp; Accretion of debt issuance costs | 21000 | 24000 |
| Non cash lease expense | 133000 | 157000 |
| Accretion of unfavorable lease position | (5000) | (26000) |
| Stock-based compensation expense | 101000 | 89000 |
| Changes in operating assets and liabilities: |  |  |
| Receivables | 1003000 | 2127000 |
| Prepaid expenses and other assets | (29000) | 576000 |
| Accounts payable and accrued liabilities | 400000 | (883000) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Related party liabilities | 319000 | 59000 |
| Lease liabilities | (126000) | (157000) |
| Net cash provided by operating activities | 2149000 | 2503000 |
| **Investing activities:** |  |  |
| Payment for purchases of property and equipment | (41000) | (4015000) |
| Net cash used in investing activities | (41000) | (4015000) |
| **Financing activities:** |  |  |
| Principal payments on long-term debt | (472000) | (280000) |
| Advances on line of credit |  | 2000000 |
| &nbsp;&nbsp;&nbsp; Capital contribution non-controlling interests |  | 8000 |
| Distributions to non-controlling interests | (125000) |  |
| Net cash (used in) provided by financing activities | (597000) | 1728000 |
| Net change in cash, cash equivalents, and restricted cash | 1511000 | 216000 |
| Cash, cash equivalents, and restricted cash at beginning of period | 3712000 | 11275000 |
| Cash, cash equivalents, and restricted cash at end of period | $5223000 | $11491000 |
| **Supplemental cash flow disclosure** |  |  |
| Cash paid during the period for: |  |  |
| Interest | $257000 | $409000 |
| Income tax (refunds) | $(316000) | $129000 |
| **Schedule of non-cash investing and financing activities** |  |  |
| Equipment included in accounts payable and accrued liabilities | $400000 | $2160000 |
| **Detail of cash, cash equivalents and restricted cash at end of period** |  |  |
| &nbsp;&nbsp;&nbsp; Cash and cash equivalents | $4973000 | $11241000 |
| &nbsp;&nbsp;&nbsp; Restricted cash | 250000 | 250000 |
| Cash, cash equivalents, and restricted cash at end of period | $5223000 | $11491000 |

---

See accompanying notes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4

------

AMERICAN SHARED HOSPITAL SERVICES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(Unaudited)

**Note *1.***&nbsp;&nbsp;&nbsp;&nbsp;**Basis of Presentation**

In the opinion of the management of American Shared Hospital Services ("ASHS"), the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary for the fair presentation of ASHS consolidated financial position as of *March 31, 2026*, the results of its operations for the *three*-month periods ended *March 31, 2026* and *2025*, and the cash flows for the *three*-month periods ended *March 31, 2026* and *2025*. The results of operations for the *three*-month periods ended *March 31, 2026* are *not* necessarily indicative of results on an annualized basis. Consolidated balance sheet amounts as of *December 31, 2025* have been derived from the audited consolidated financial statements.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended *December 31, 2025* included in the ASHS Annual Report on Form *10*-K filed with the Securities and Exchange Commission ("SEC") on *March 31, 2026.*

These condensed consolidated financial statements include the accounts of ASHS and its subsidiaries (the "Company") including as follows: ASHS wholly owns the subsidiaries American Shared Radiosurgery Services ("ASRS"), PBRT Orlando, LLC ("Orlando"), ASHS-Mexico, S.A. de C.V. ("ASHS-Mexico"), ASHS-Rhode Island Proton Beam Radiation Therapy, LLC ("RI-PBRT"), ASHS-Bristol Radiation Therapy, LLC ("Bristol"), and MedLeader.com, Inc. ("MedLeader"); ASHS is the majority owner of Southern New England Regional Cancer Center, LLC ("SNERCC"), Roger Williams Radiation Therapy, LLC ("RWRT") and Long Beach Equipment, LLC ("LBE"); ASRS is the majority-owner of GK Financing, LLC ("GKF"), which wholly owns the subsidiaries Instituto de Gamma Knife del Pacifico S.A.C. ("GKPeru") and HoldCo GKC S.A. ("HoldCo"). HoldCo wholly owns the subsidiary Gamma Knife Center Ecuador S.A. ("GKCE"). ASHS-Mexico is the majority owner of AB Radiocirugia y Radioterapia de Puebla, S.A.P.I. de C.V. of Puebla ("Puebla") and Instituto Gamma Knife San Javier Mexico S.A.P.I. de C.V. ("San Javier") . GKF is the majority owner of the subsidiaries Albuquerque GK Equipment, LLC ("AGKE") and Jacksonville GK Equipment, LLC ("JGKE").

The Company (through ASRS) and Elekta AB ("Elekta"), the manufacturer of the Gamma Knife (through its wholly-owned United States subsidiary, GKV Investments, Inc.), entered into an operating agreement and formed GKF. As of *March 31, 2026*, GKF provides Gamma Knife units to seven medical centers in the United States in the states of Illinois, Indiana, Mississippi, New Mexico, New York, Oregon, and Texas. GKF also owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company through its wholly-owned subsidiary, Orlando, provided proton beam radiation therapy ("PBRT") and related equipment to a medical center in Florida.

On *June 28, 2024,* ASHS-Mexico, signed a Joint Venture Agreement with Hospital San Javier, S.A. de C.V. ("HSJ") to establish San Javier to treat public- and private-paying cancer patients and provide radiosurgery services in Guadalajara, Mexico. The Company and HSJ will hold 70% and 30% ownership interests, respectively, in San Javier. Under the agreement, the Company is responsible for upgrading HSJ's existing Gamma Knife Perfexion system to a Gamma Knife Esprit and paying 50% of all site modification costs required to install the Esprit. The Company does *not* expect that San Javier will begin treating patients until late *2026* or *2027.*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On *February 6, 2025,* the Company's subsidiary, Bristol, closed on the acquisition of certain parcels of real property located on Gooding Avenue, Bristol, Rhode Island. The purchase price for the property was $1,185,000. The transaction was effected pursuant to the terms of a Real Estate Purchase and Sale Agreement dated *November 21, 2024* by and between the Company and the sellers identified therein, with the Company having assigned its rights under that agreement to Bristol effective *February 5, 2025.* 

The Company formed the subsidiaries Puebla, GKPeru, ASHS-Mexico, and acquired GKCE for the purposes of expanding its business internationally; Orlando and LBE to provide PBRT equipment and services in Orlando, Florida and Long Beach, California, respectively; and AGKE and JGKE to provide Gamma Knife equipment and services in Albuquerque, New Mexico and Jacksonville, Florida, respectively. LBE is *not* expected to generate revenue within the next *two* years.

MedLeader was formed to provide continuing medical education online and through videos for doctors, nurses, and other healthcare workers. MedLeader is *not* operational at this time.

All significant intercompany accounts and transactions have been eliminated in consolidation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *5*

------

**Accounting pronouncements issued and adopted -** In *December 2023,* the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") *2023*-*09 Income Taxes (Topic *740*) Improvements to Income Tax Disclosures* ("ASU *2023*-*09"*) which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign. ASU *2023*-*09* is effective for annual periods beginning after *December 15, 2024.* The Company adopted ASU *2023*-*09* for the year-ended *December 31, 2025,* prospectively, and enhanced its disclosure requirements, accordingly.

In *July 2025,* the FASB issued ASU *2025*-*05 Measurement of Credit Losses for Accounts Receivable and Contract Assets* ("ASU *2025*-*05"*) which provides (*1*) all entities with a practical expedient and (*2*) entities other than public business entities, with an accounting policy election when estimating credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic *606.* ASU *2025*-*05* is effective for annual reporting periods beginning after *December 15, 2025* and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have *not* yet been issued or made available for issuance. The Company adopted ASU *2025*-*05* for the period-ended *March 31, 2026* and concluded it did *not* have a material impact to its condensed consolidated financial statements.

**Accounting pronouncements issued and *not* yet adopted -** In *November 2024,* the FASB issued ASU *2024*-*03 Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures* ("ASU *2024*-*03"*) which requires entities to *1.* disclose amounts of (a) purchase of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and, (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities, *2.* include certain amounts that are already required to be disclosed under current Generally Accepted Accounting Principles in the same disclosures as other disaggregation requirements, *3.* disclose a qualitative description of the amounts remaining in relevant expense captions that are *not* necessarily disaggregated quantitatively, and *4.* disclose the total amount of selling expenses, in annual reporting periods, including an entity's definition of selling expense. ASU *2024*-*03* is effective for annual reporting periods beginning after *December 15, 2026,* and interim reporting periods beginning after *December 15, 2027.* Early adoption is permitted. The Company is currently evaluating ASU *2024*-*03* to determine the impact it *may* have on its consolidated financial statements.

**Revenue recognition** - The Company recognizes revenues under Accounting Standards Codification ("ASC") *842 Leases* ("ASC *842"*) and ASC *606 Revenue from Contracts with Customers* ("ASC *606"*).

*Rental revenue from medical equipment leasing (*"*leasing*"*)* – The Company recognizes revenues under ASC *842* when services have been rendered and collectability is reasonably assured, on either a fee per use or revenue sharing basis. The terms of the contracts do *not* contain any guaranteed minimum payments. The Company's lease contracts typically have a ten-year term and are classified as either fee per use or revenue sharing. Fee per use revenues are recognized at the time the procedures are performed, based on each hospital's contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company's revenue sharing arrangements also have a cost sharing component. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. The operating costs are recorded as other direct operating costs in the condensed consolidated statements of operations. For the *three*-month period ended *March 31, 2026*, the Company recognized leasing revenue of approximately $3,020,000 compared to $2,991,000 for the same period in the prior year. For the *three*-month period ended *March 31, 2026*, $1,956,000 of the ASC *842* revenues were for PBRT services compared to $1,642,000, for the same period in the prior year.

*Direct patient services income* – The Company has stand-alone facilities in Lima, Peru, Guayaquil, Ecuador, and Puebla, Mexico where contracts exist between the Company's facilities and the individual patients treated at the facility. Under ASC *606,* the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife or radiation therapy treatment. Revenue related to these treatments is recognized on a gross basis at the time when the patient receives treatment. There is *no* variable consideration present in the Company's performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net *30* days. GKCE's patient population is primarily covered by a government payor and payments are paid between *three* and *six* months following issuance of an invoice. The facility in Puebla currently has a contract with one local hospital to cover its eligible patient base and is also treating self-pay patients. Puebla's payment terms are typically prepaid for self-pay patients and net *30* days for the hospital patients. The Company did *not* capitalize any incremental costs related to the fulfillment of its customer contracts.

The Company holds a 60% equity interest in each of SNERCC and RWRT (collectively, the "RI Companies") and was assigned certain payor contracts for a purchase price of $2,850,000, in *May 2024 (*such transaction, the "RI Acquisition"). The RI Companies operate three, existing, stand-alone radiation therapy cancer centers in Woonsocket, Warwick and Providence, Rhode Island, where contracts exist between the Company's facilities and the individual patients treated at the facility. Under ASC *606,* the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of radiation therapy treatment. Revenue related to radiation therapy is recognized at the expected amount to be received, based on insurance contracts and payor mix, when the patient receives treatment. There is *no* variable consideration present in the Company's performance obligation and the transaction price is agreed upon per the stated contractual rate. Payment terms at these facilities are typically prepaid for self-pay patients and insurance providers are paid net 30 to 60 days. The Company did *not* capitalize any incremental costs related to the fulfillment of its customer contracts. The Company also concluded the three facilities are part of its direct patient services segment, see further discussion below.

Accounts receivable balances under ASC *606* at *March 31, 2026* and *January 1, 2026* were $8,484,000 and $8,138,000, respectively. Accounts receivable balances under ASC *606* at *March 31, 2025* and *January 1, 2025* were $6,120,000 and $6,073,000, respectively. For the *three*-month period ended *March 31, 2026*, the Company recognized direct patient services revenues of approximately $4,064,000 compared to $3,121,000 for the same period in the prior year.

**Liquidity** - On *April 9, 2021,* ASHS, Orlando, GKF (together with ASHS and Orlando, the "Borrowers"), and ASRS (together with the Borrowers, collectively, the "Loan Parties") entered into a *five*-year $22,000,000 credit agreement (the "Credit Agreement") with Fifth Third Bank, N.A. ("Fifth Third"). The loan entered into with United States International Development Finance Corporation ("DFC") in connection with the acquisition of GKCE in *June 2020 (*the "DFC Loan"; together with the Credit Agreement, the "Credit Agreements") was obtained through the Company's wholly-owned subsidiary, HoldCo and is guaranteed by GKF. On *December 10, 2025,* the Loan Parties received a notice from Fifth Third asserting that a specified Event of Default (as defined in the Credit Agreement) occurred under the Credit Agreement due to the Borrower's failure to maintain minimum unrestricted domestic cash of at least an aggregate of $5,000,000 (the "Minimum Cash Covenant") as of *September 30, 2025.* As of *December 31, 2025,* the Company was *not* in compliance with the minimum fixed-charge coverage ratio, the maximum funded debt-to-EBITDA ratio, and the Minimum Cash Covenant required by the Credit Agreement, and the Company notified Fifth Third of such defaults.

ASHS has also determined that the Borrowers' defaults under the Credit Agreement could be deemed to have resulted in an Event of Default (as defined in the DFC Loan) under the DFC Loan. However, as of the date of this Quarterly Report, DFC has *not* delivered any notice asserting that such an Event of Default has occurred or sought to exercise any remedies it *may* have under the DFC Loan.

The Credit Agreement matured on *April 9, 2026* and is secured by a lien on substantially all of the assets of the Loan Parties and is guaranteed by ASHS, Orlando and ASRS. The Loan Parties did *not* satisfy all outstanding obligations under the Credit Agreement on the maturity date. ASHS is currently in discussions with Fifth Third regarding a potential amendment and extension of the maturity date of the Credit Agreement. However, there can be *no* assurance that Fifth Third will agree to such an extension or, if obtained, as to the terms or duration of any such extension. If ASHS is unable to obtain an extension of the maturity date of the Credit Agreement, and Fifth Third were to demand payment in Full in lump-sum, the Company will *not* have sufficient cash on hand to repay all outstanding obligations due under the Credit Agreement at maturity. See Note *3* - "Long Term Debt" for additional information.

As of *March 31, 2026*, HoldCo was *not* in compliance with the cash-to-debt covenant under the DFC Loan. The Company notified DFC of this non-compliance and is in discussions for an extended waiver or amendment to the DFC Loan, but there can be *no* assurances regarding the outcome of such discussions. Furthermore, ASHS has determined that HoldCo's non-compliance with the DFC Loan could be deemed to have resulted in an Event of Default (as defined in the Credit Agreement) of the Credit Agreement with Fifth Third. However, as of the date of this Quarterly Report, Fifth Third has *not* delivered any notice to the Loan Parties asserting that such an Event of Default has occurred or sought to exercise any remedies it *may* have under the Credit Agreement.&nbsp;&nbsp;&nbsp;&nbsp;

The Company reassessed its ability to continue as a going concern in light of the Events of Default discussed above. As long as the Company remains in default under the Credit Agreements, Fifth Third and DFC could accelerate all payment obligations under the Credit Agreements. If Fifth Third or DFC were to accelerate all payment obligations under the Credit Agreements as a result of the defaults thereunder, the Company would *not* have sufficient cash on hand to satisfy such accelerated payment obligations. As a result, these conditions raise substantial doubt about the Company's ability to continue as a going concern. To date, the Company has *not* negotiated a definitive extension and, if the Company is ultimately unable to do so, the Company's liquidity will be adversely impacted and the Company's ability to satisfy all of its commitments over the next *twelve* months in accordance with their current terms would be jeopardized. As a result of these conditions, in connection with management's assessment of going-concern considerations in accordance with ASC **205*-*40* Presentation of Financial Statements - Going Concern*, management has determined that the Company's liquidity condition raises substantial doubt about the Company's ability to continue as a going concern. The Company's condensed consolidated balance sheet as of *March 31, 2026*, does *not* contain any adjustments that might result from the uncertainty regarding the Company's ability to continue as a going concern.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *6*

------

**Business segment information** - Based on the guidance provided in accordance with ASC *280 Segment Reporting* ("ASC *280"*), the Company analyzed its subsidiaries which are all in the business of providing radiosurgery and radiation therapy services, either through leasing to healthcare providers or directly to patients, and concluded there are two reportable segments, leasing and direct patient services. As of *March 31, 2026*, the Company provided Gamma Knife and PBRT equipment to eight hospitals in the United States, which constitutes the leasing segment. As of *March 31, 2026*, the Company owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador, one single-unit radiation therapy facility in Puebla, Mexico and the Company also owns a majority interest in and operates, three single-unit radiation therapy facilities in Rhode Island, which collectively constitute the direct patient services segment.

An operating segment is defined by ASC *280* as a component of an entity that engages in business activities in which it *may* recognize revenues and incur expenses, that has operating results that are regularly reviewed by the Company's Chief Operating Decision Maker ("CODM"), and for which its discrete financial information is available. The Company determined two reportable segments existed due to similarities in economics of business operations and how the Company recognizes revenue for the patient treatment. The operating results of the two reportable segments are reviewed by the Company's Executive Chairman of the Board, who is also the CODM.

For the *three*-month periods ended *March 31, 2026* and *2025*, the Company's PBRT operations represented a majority of the revenue and net income of the leasing segment, which reported an overall net loss for the period. The revenues, depreciation, amortization, and other expense, interest expense, interest income, income tax expense (benefit), net (loss) income attributable to American Shared Hospital Services, and total assets for the Company's two reportable segments as of *March 31, 2026* and *2025* consist of the following:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Revenues |  |  |
| Leasing | $3020000 | $2991000 |
| Direct patient services | 4064000 | 3121000 |
| Total | $7084000 | $6112000 |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Depreciation, amortization, and other expense |  |  |
| Leasing | $859000 | $899000 |
| Direct patient services | 435000 | 550000 |
| Total | $1294000 | $1449000 |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Interest expense |  |  |
| Leasing | $285000 | $398000 |
| Direct patient services | 17000 | 35000 |
| Total | $302000 | $433000 |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Interest income |  |  |
| Leasing | $33000 | $58000 |
| Direct patient services | 20000 | 16000 |
| Total | $53000 | $74000 |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Income tax expense (benefit) |  |  |
| Leasing | $(40000) | $(257000) |
| Direct patient services | 132000 | (66000) |
| Total | $92000 | $(323000) |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Net loss attributable to American Shared Hospital Services |  |  |
| Leasing | $(156000) | $(303000) |
| Direct patient services | (456000) | (322000) |
| Total | $(612000) | $(625000) |

---

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| Total assets |  |  |
| Leasing | $23821000 | $24334000 |
| Direct patient services | 30904000 | 31145000 |
| Total | $54725000 | $55479000 |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Leasing revenue |  |  |
| Domestic | $3020000 | $2991000 |
| Total | $3020000 | $2991000 |

---

---

| | | |
|:---|:---|:---|
|  | ***2026*** | ***2025*** |
| Direct patient service revenue |  |  |
| International | $1912000 | $1181000 |
| Domestic | 2152000 | 1940000 |
| Total | $4064000 | $3121000 |

---

**Reclassification** - Certain comparative balances as of *December 31, 2025* have been reclassified to make them consistent with the current year presentation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *7*

------

**Note *2.***&nbsp;&nbsp;&nbsp;&nbsp;**Property and Equipment**

Property and equipment are stated at cost less accumulated depreciation. Depreciation for Gamma Knife equipment, LINAC units and other equipment is determined using the straight-line method over the estimated useful lives of the assets, which for medical and office equipment is generally between three and ten years, and after accounting for salvage value on the equipment where applicable.

Depreciation for PBRT equipment is determined using the modified units of production method, which is a function of both time and usage of the equipment. This depreciation method allocates costs considering the projected volume of usage through the useful life of the PBRT unit, which has been estimated at 20 years. The estimated useful life of the PBRT unit is consistent with the estimated economic life of 20 years.

The following table summarizes property and equipment as of *March 31, 2026* and *December 31, 2025*:

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| Medical equipment and facilities | $70259000 | $70172000 |
| Office equipment | 643000 | 638000 |
| Construction in progress | 205000 | 255000 |
|  | 71107000 | 71065000 |
| Accumulated depreciation | (41238000) | (39943000) |
| Net property and equipment | $29869000 | $31122000 |
| Net property and equipment held outside of the United States | $7887000 | $8082000 |

---

Depreciation expense recorded in costs of revenue and selling and administrative expense in the condensed consolidated statements of operations for the *three*-month periods ended *March 31, 2026* and *2025* is as follows:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Depreciation expense | $1294000 | $1449000 |

---

**Note *3.***&nbsp;&nbsp;&nbsp;&nbsp;**Long-Term Debt Financing**

On *April 9, 2021,* the Borrowers, and the Loan Parties entered into a *five* year $22,000,000 Credit Agreement with Fifth Third. The Credit Agreement includes three loan facilities. The *first* loan facility is a $9,500,000 term loan (the "Term Loan") which was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs. The *second* loan facility of $5,500,000 is a delayed draw term loan (the "DDTL") which was used to refinance the Company's PBRT finance leases and associated closing costs, as well as to provide additional working capital. The *third* loan facility provides for a $7,000,000 revolving line of credit (the "Revolving Line") available for future projects and general corporate purposes. The facilities have a five-year maturity, which matured on *April 9, 2026,* and carry a floating interest rate based on the Secured Overnight Financing Rate ("SOFR") plus 3.0% (6.86% as of *March 31, 2026*) and are secured by a lien on substantially all of the assets of the Loan Parties and guaranteed by ASHS, Orlando and ASRS. There was an aggregate of $7,075,000 due on *April 9, 2026* for the Term Loan and DDTL.

On *January 25, 2024 (*the "First Amendment Effective Date"), the Company and Fifth Third entered into a First Amendment to Credit Agreement (the "First Amendment"), which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the "Supplemental Term Loan"). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on *January 25, 2024,* and were used for capital expenditures related to the Company's operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on *January 25, 2030 (*the "Maturity Date"). Interest on the Supplemental Term Loan was payable monthly during the initial *twelve* month period following the First Amendment Effective Date. Following that *twelve* month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

On *December 18, 2024 (*the "Second Amendment Effective Date"), the Company and Fifth Third entered into a Second Amendment to the Credit Agreement (the "Second Amendment"), which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $7,000,000 (the "Second Supplemental Term Loan"). The proceeds of the Second Supplemental Term Loan were advanced in a single borrowing on *December 18, 2024,* and were used for capital expenditures related to the Company's domestic Gamma Knife leasing operations and the RI Acquisition and related transaction costs. The Second Supplemental Term Loan will mature on *December 18, 2029 (*the "Second Maturity Date"). Interest on the Second Supplemental Term Loan is payable monthly during the initial *twelve* month period following the Second Amendment Effective Date. Following such *twelve* month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Second Supplemental Term Loan over a period of *seven* years. All unpaid principal of the Second Supplemental Term Loan and accrued and unpaid interest thereon is due and payable in full on the Second Maturity Date. The Second Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

The long-term debt on the condensed consolidated balance sheets related to the Term Loan, DDTL, Revolving Line, Supplemental Term Loan and Second Supplemental Term Loan was $15,895,000 and $16,197,000 as of *March 31, 2026* and *December 31, 2025*, respectively. The Company did not capitalize any debt issuance costs as of *March 31, 2026* and *December 31, 2025*, related to the issuance of the Supplemental Term Loan and Second Supplemental Term Loan.

The Credit Agreement contains customary covenants and representations, including without limitation, a minimum fixed charge coverage ratio of 1.25 and maximum funded debt to EBITDA ratio of 3.0 to *1.0* (tested on a trailing *twelve*-month basis at the end of each fiscal quarter), an obligation that the Company maintain $5,000,000 of unrestricted cash, reporting obligations, limitations on dispositions, changes in ownership, mergers and acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and capital expenditures.

On *September 30, 2025,* the Company received a limited waiver from Fifth Third with respect to its failure to be in compliance with the maximum funded debt to EBITDA ratio covenant in the Credit Agreement as of *June 30, 2025* and with respect to the delivery of items following the closing of the Second Amendment.

As previously disclosed, (i) on *December 10, 2025,* the Loan Parties received notice from Fifth Third asserting that an Event of Default had occurred under the Credit Agreement due to the Borrowers' failure to comply with the Minimum Cash Covenant as of *September 30, 2025,* and (ii) as of *December 31, 2025,* the Company was *not* in compliance with the minimum fixed-charge coverage ratio, the maximum funded debt-to-EBITDA ratio, and the Minimum Cash Covenant required by the Credit Agreement and notified Fifth Third of such non-compliance (all such defaults in clauses (i) and (ii), collectively, the "Financial Covenant Defaults"). The Financial Covenant Defaults under the Credit Agreement remain uncured as of *March 31, 2026,* and, as a result, the Loan Parties are *not* in compliance with the Credit Agreement as of such date.

Due to the Financial Covenant Defaults described above, Fifth Third *may* exercise any of its rights, powers, privileges, and remedies under the Credit Agreement, the other Loan Documents, and applicable law, including but *not* limited to the right to accelerate the Borrowers' payment obligations under the Credit Agreement.

In *December 2025,* as a result of the Financial Covenant Defaults, Fifth Third notified the Company that, among other things, it had suspended the Revolving Loan Commitment with respect to additional Revolving Loan Advances. To date, Fifth Third has *not* accelerated the obligations of the Loan Parties under the Credit Agreement or other Loan Documents

The Loan Parties did *not* satisfy all outstanding obligations under the Credit Agreement when it matured on *April 9, 2026.* Due to the Financial Covenant Defaults described above, the Loan Parties are *not* in compliance with the Credit Agreement as of *March 31, 2026*. To date, Fifth Third has *not* accelerated the obligations of the Loan Parties under the Credit Agreement or other Loan Documents. ASHS is currently in discussions with Fifth Third regarding an amendment to extend the maturity date of the Credit Agreement. However, there can be *no* assurances regarding the outcome of such discussions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *8*

------

The loan entered into with DFC in connection with the acquisition of GKCE in *June 2020* was obtained through the Company's wholly-owned subsidiary, HoldCo and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE's assets. The *first* tranche of the DFC Loan was funded in *June 2020.* During the *fourth* quarter of *2023,* the *second* tranche of the DFC loan was funded to finance the equipment upgrade in Ecuador. The amount outstanding under the *first* tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%. The amount outstanding under the *second* tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The Company did not capitalize any debt issuance costs as of *March 31, 2026* and *December 31, 2025*, related to the maintenance and administrative fees on the DFC Loan. The long-term debt on the condensed consolidated balance sheets related to the DFC Loan was $985,000 and $1,149,000 as of *March 31, 2026* and *December 31, 2025*, respectively.

The DFC Loan contains customary covenants including without limitation, requirements that HoldCo maintain certain financial ratios related to liquidity and cash flow as well as depository requirements. On *March 28, 2024,* HoldCo received a waiver and amendment from DFC for certain covenants as of *December 31, 2023* and through *December 31, 2024,* and amended other covenants and definitions permanently. On *March 3, 2025,* the Company received an additional waiver from DFC for certain covenants as of *December 31, 2024* and through *December 31, 2025.* HoldCo was *not* in compliance with the cash to debt covenant at *March 31, 2026*.

As a result of the Loan Parties' Financial Covenant Defaults under the Credit Agreement with Fifth Third discussed above, ASHS has determined that the non-compliance with the Credit Agreement could be deemed to have resulted in an Event of Default (as defined in the DFC Loan) under the DFC Loan. However, as of the date of this Quarterly Report, DFC has *not* delivered any notice to HoldCo or ASHS asserting the occurrence of an Event of Default resulting from the Financial Covenant Defaults or sought to exercise any remedies it *may* have under the DFC Loan.

Additionally, HoldCo was *not* in compliance with the cash-to-debt covenant under the DFC Loan as of *March 31, 2026.* The Company notified DFC of this non-compliance and is in discussions for an extended waiver or amendment to the DFC Loan. However, there can be *no* assurances regarding the outcome of such discussions.

Furthermore, ASHS has determined that HoldCo's non-compliance with the DFC Loan could be deemed to have resulted in an Event of Default (as defined in the Credit Agreement) under the Credit Agreement with Fifth Third. However, as of the date of this Quarterly Report, Fifth Third has *not* delivered any notice to the Loan Parties asserting that such an Event of Default has occurred or sought to exercise any remedies it *may* have under the Credit Agreement as a result thereof.

The Company's failure to comply with the covenants under the Credit Agreements could result in the Company's credit commitments being terminated and the principal of any outstanding borrowings, together with any accrued but unpaid interest, under the Credit Agreements could be declared immediately due and payable. Furthermore, the lenders under the Credit Agreements could also exercise their rights to take possession of, and to dispose of, the collateral securing the credit facilities and loans and could pursue additional default remedies upon default as set forth in each such agreement.

As long as the Company remains in default under the Credit Agreements, Fifth Third and DFC could accelerate all payment obligations under the Credit Agreements. If Fifth Third or DFC were to accelerate all payment obligations under the Credit Agreements as a result of the defaults thereunder, the Company would *not* have sufficient cash on hand to satisfy such accelerated payment obligations. As a result, these conditions raise substantial doubt about the Company's ability to continue as a going concern.

In *November* and *December 2024,* GKCE obtained *two* loans with banks locally in Ecuador (the "GKCE Loans"). The GKCE Loans carry interest rates of 12.60% and 12.78% and are payable in twelve and thirty-six equal monthly installments of principal and interest, respectively. The Company did *not* capitalize any debt issuance costs related to the GKCE Loans. Total long-term debt on the condensed consolidated balance sheets related to the GKCE Loans was $47,000 and $53,000 as of *March 31, 2026* and *December 31, 2025*, respectively.

The accretion of debt issuance costs for the *three*-month period ended *March 31, 2026* was $21,000 compared to $24,000 for the same period in the prior year. As of *March 31, 2026* and *December 31, 2025*, the unamortized deferred issuance costs on the condensed consolidated balance sheet was $84,000 and $105,000, respectively.

As of *March 31, 2026*, long-term debt on the condensed consolidated balance sheets was $16,843,000. The following are contractual maturities of long-term debt as of *March 31, 2026*, excluding deferred issuance costs of $84,000:

---

| | |
|:---|:---|
| **Year ending December 31,** | ***Principal*** |
| 2026 (excluding the three-months ended March 31, 2026) | $8827000 |
| 2027 | 2058000 |
| 2028 | 1540000 |
| 2029 | 4457000 |
| 2030 | 45000 |
|  | $16927000 |

---

**Note *4.* Other Accrued Liabilities**

Other accrued liabilities consist of the following as of *March 31, 2026* and *December 31, 2025*:

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| Professional services | $317000 | 141000 |
| Operating costs | 986000 | 1026000 |
| Other | 620000 | 585000 |
| Total other accrued liabilities | $1923000 | $1752000 |

---

**Note *5.***&nbsp;&nbsp;&nbsp;&nbsp;**Leases**

The Company determines if a contract is a lease at inception. Under ASC *842,* the Company is a lessor of equipment to various customers. Leases that commenced prior to the ASC *842* adoption date were classified as operating leases under historical guidance. As the Company has elected the package of practical expedients allowing it to *not* reassess lease classification, these leases are classified as operating leases under ASC *842* as well, as applicable. All of the Company's lessor arrangements entered into or modified after ASC *842* adoption are also classified as operating leases. Some of these lease terms have an option to extend the lease after the initial term, but do *not* contain the option to terminate early or purchase the asset at the end of the term. The Company has elected *not* to recognize right-of-use ("ROU") assets and lease liabilities that arise from short-term (*12* months or less) leases for any class of underlying asset.

The Company's Gamma Knife and PBRT contracts with health systems are classified as operating leases under ASC *842.* The related equipment is included in medical equipment and facilities on the Company's condensed consolidated balance sheets. As all income from the Company's lessor arrangements is solely based on procedure volume, all income is considered variable payments *not* dependent on an index or a rate. As such, the Company does *not* measure future operating lease receivables.

On *March 13, 2026,* the Company and Orlando Health, Inc. ("Orlando Health") entered into Amendment Two to Proton Beam Radiation Therapy Lease Agreement (the "Amendment"). The Amendment extends the term of the Proton Beam Radiation Therapy Lease Agreement dated *October 18, 2006* between the Company and Orlando Health, as amended by Amendment One to Proton Beam Radiation Therapy Lease Agreement dated effective as of *August 12, 2012 (*the "Lease") for an additional seven years commencing *April 6, 2026* through *April 5, 2033 (*the "Extended Term"), and sets the lease payment terms during the Extended Term based on a technical component collection percentage with that percentage decreasing during certain of the *twelve* month periods of the Extended Term. The Amendment amends certain other terms of the Lease and sets forth certain agreements between the parties with respect to the leased equipment, including (i) an option granted to Orlando Health whereby it *may* elect to purchase the leased equipment at the end of the lease term, including setting the purchase price and the period in which Orlando Health *may* exercise its option, (ii) matters related to the Company's obligation to remove, at its expense, the leased equipment from Orlando Health at the end of the Extended Term in the event Orlando Health does *not* exercise its purchase option, and certain financial understandings of the parties related to that obligation, and (iii) maintenance and insurance coverage obligations of the parties.

The Company has *two* sublease agreements for small, corporate office spaces in San Francisco, California and Downers Grove, Illinois. The sublease in San Francisco is for 80 square feet for $1,003 per month located at *601* Montgomery Street, Suite *850.* The sublease in Downers Grove was signed in *February 2025* and is for *two* offices and *three* cubicle spaces for $2,300 per month located at *3041* Woodcreek Drive. Total ROU assets and lease liabilities for the Downers Grove sublease were $26,000. The sublease for Downers Grove expired in *January 2026* and was *not* renewed.

The RI Companies operate three single-unit radiation therapy facilities. The Company assessed the existing lease agreements under ASC *842* and concluded two of the three facilities contained operating leases. The facility in Woonsocket, RI has a ground lease with a sublease for 1,950 square feet of the clinic space, which is leased back to the lessor. The facility in Warwick, RI has a lease for 10,236 square feet for $32,790 per month. The facility in Providence, RI also has a ground lease, which was contributed by *one* of the minority partners.

On *January 1, 2025,* the Company entered into the Amended and Restated Lease Agreement (the "Amended Lease") for the facility lease in Warwick, Rhode Island. The Amended Lease includes a lease extension to *December 31, 2039* and modified the monthly lease payment to $26,443. The Company assessed the Amended Lease under ASC *842* and concluded it was a lease modification. On *January 1, 2025,* the effective date of the Amended Lease, the Company recorded additional ROU asset and lease liability in the amount of $1,922,000.

The Company owns and operates a stand-alone Gamma Knife facility in Lima, Peru where it leased approximately 1,600 square feet for approximately $8,850 per month through *June 2025.* In *May 2024,* the Company executed a new lease agreement for approximately 7,704 square feet for $9,000 per month. The Company renovated this space during the *first* half of *2025* to accommodate its Gamma Knife Esprit and administrative offices and moved into the leased space in *June 2025.* The current lease expires in *May 2034.* Total ROU asset and lease liability for the Peru lease was $771,000.

The Company also owns and operates a stand-alone Gamma Knife facility in Guayaquil, Ecuador where it owns 864 square feet of condominium space in an office building and approximately 10,135 of related land and parking spaces. The Company's stand-alone radiation therapy facility in Puebla, Mexico also has a lease for approximately 536 square meters for $1,800 per month with a lease expiration in *July 2034.* The lease in Puebla is with a related party. Total ROU assets and lease liabilities for the Puebla lease were $149,000.

Sublease income for the *three*-month period ended *March 31, 2026* was $15,000 compared to $15,000 for the same period in the prior year.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *9*

------

The Company's lessee operating leases are accounted for as ROU assets, current portion of lease liabilities, and lease liabilities on the condensed consolidated balance sheets. Operating lease ROU assets and liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. The Company's operating lease contracts do *not* provide an implicit rate for calculating the present value of future lease payments. The Company determined its incremental borrowing rate to be approximately 8% by using available market rates and expected lease terms. The operating lease ROU assets and liabilities include any lease payments made and there were *no* lease incentives or initial direct costs incurred. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. The Company's lessee operating lease agreements are for administrative office space and related equipment and for its direct patient service facilities in Lima, Peru, Puebla, Mexico and two stand-alone facilities in Rhode Island in which the Company acquired an interest in the RI Acquisition. These leases have remaining lease terms of approximately 8 to 15 years, some of which include options to renew or extend the lease. As of *March 31, 2026*, operating ROU assets, net of unfavorable leasehold interests, were $3,610,000, and lease liabilities were $4,343,000.

The following table summarizes the maturities of the Company's lessee operating lease liabilities as of *March 31, 2026*:

---

| | |
|:---|:---|
| Year ending December 31, | ***Operating Leases*** |
| 2026 (excluding the three-months ended March 31, 2026) | $375000 |
| 2027 | 510000 |
| 2028 | 520000 |
| 2029 | 536000 |
| 2029 | 550000 |
| Thereafter | 4713000 |
| Total lease payments | 7204000 |
| Less imputed interest | (2861000) |
| Total | $4343000 |

---

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| **Lease cost** |  |  |
| Operating lease cost | $133000 | $157000 |
| Sublease income | (15000) | (15000) |
| Total lease cost | $118000 | $142000 |
| **Other information** |  |  |
| Cash paid for amounts included in the measurement of lease liabilities - Operating leases | $126000 | $655000 |
| Weighted-average remaining lease term - Operating leases in years | 12.83 | 14.70 |
| Weighted-average discount rate - Operating leases | 8.19% | 8.25% |

---

**Note *6.***&nbsp;&nbsp;&nbsp;&nbsp;**Per Share Amounts**

Per share information has been computed based on the weighted average number of common shares and dilutive common share equivalents outstanding. The Company calculates diluted shares using the treasury stock method. Because the Company reported a loss for the *three*-month periods ended *March 31, 2026* and *2025*, the potentially dilutive effects of approximately 2,000 of the Company's stock options and 211,000 of the Company's unvested restricted stock awards, and 38,000 of the Company's stock options and 173,000 of the Company's unvested restricted stock awards were *not* considered for the reporting periods, respectively. The weighted average common shares outstanding for basic earnings per share for the *three*-month periods ended *March 31, 2026* and *2025* included approximately 123,000 and 123,000, respectively, of the Company's restricted stock awards that are fully vested but are deferred for issuance.

The following table sets forth the computation of basic and diluted earnings per share for the *three*-month periods ended *March 31, 2026* and *2025*:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Net loss attributable to American Shared Hospital Services | $(612000) | $(625000) |
| Weighted average common shares for basic loss per share | 6725000 | 6572000 |
| Weighted average common shares for diluted loss per share | 6725000 | 6572000 |
| Basic loss per share | $(0.09) | $(0.10) |
| Diluted loss per share | $(0.09) | $(0.10) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *10*

------

**Note *7.***&nbsp;&nbsp;&nbsp;&nbsp;**Income Taxes**

The Company generally calculates its effective income tax rate at the end of an interim period using an estimate of the annualized effective income tax rate expected to be applicable for the full fiscal year. However, when a reliable estimate of the annualized effective income tax rate cannot be made, the Company computes its provision for income taxes using the actual effective income tax rate for the results of operations reported within the year-to-date periods. The Company's effective income tax rate is highly influenced by relative income or losses reported and from the results of international operations. A small change in estimated annual pretax income can produce a significant variance in the annualized effective income tax rate given the expected amount of these items. As a result, the Company has computed its provision for income taxes for the *three*-month periods ended *March 31, 2026* and *2025* by applying the actual effective tax rates to income or reported within the condensed consolidated financial statements through those periods. The provision for income taxes for the *three*-month period ended *March 31, 2026*, included a non-recurring adjustment for unrecognized tax benefits related to foreign taxes of $31,000. For the *three*-month period ended *March 31, 2025*, the Company recorded a $71,000 adjustment for unrecognized tax benefits related to foreign taxes.

On *July 4, 2025,* President Donald Trump signed the One Big Beautiful Bill Act ("OBBBA") into law, which is considered the enactment date under U.S. GAAP. This legislation introduces several provisions affecting businesses, including the permanent extension of certain expiring elements of the Tax Cuts and Jobs Act, modifications to the international tax framework, and favorable tax treatment for certain other business provisions. Key corporate tax provisions include existing *21%* corporate income tax rate made permanent, the restoration of *100%* bonus depreciation, immediate expensing for domestic research and experimental expenditures, changes to Section *163*(j) interest limitations, updates to Global Intangible Low Tax Income (GILTI) and Foreign- Derived Intangible Income (FDII) rules, amendments to energy credits, and expanded Section *162*(m) aggregation requirements. The OBBBA contains multiple effective dates, with some provisions applicable beginning in *2026.* The legislation does *not* impact the Company's prior years' financial statements.

**Note *8.***&nbsp;&nbsp;&nbsp;&nbsp;**Commitments**

As of *March 31, 2026*, the Company had commitments to purchase and install *two* Esprit and *two* LINAC systems. The Esprit upgrades and *one* LINAC installation are anticipated to occur in late *2026* or later at existing customer sites. The remaining LINAC is reserved for a future customer site. Total Gamma Knife and LINAC commitments as of *March 31, 2026* were $7,884,000. There are *no* deposits on the condensed consolidated balance sheets related to these commitments as of *March 31, 2026* and *December 31, 2025*, nor are there any penalties if the Company decides to *not* execute on these commitments. Although the Company's current intent is to finance substantially all of these commitments, there can be *no* assurance that financing will be available for the Company's current or future projects, or at terms that are acceptable to the Company. However, the Company currently has cash on hand of $5,223,000.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As of *March 31, 2026*, the Company had commitments to service and maintain its Gamma Knife, LINAC, and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta, Solutech, and Mobius Imaging, LLC. The Company's commitment to purchase *one* LINAC system also includes a 5-year agreement to service the equipment. Total service commitments as of *March 31, 2026* were $5,705,000. The service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; *11*

------

**Note *9.***&nbsp;&nbsp;&nbsp;&nbsp;**Related Party Transactions and Balances**

The Company's Gamma Knife business is operated through its GKF subsidiary in which the Company holds an indirect 81% interest. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife. Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta, such as equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment.

The following table summarizes related party activity for the *three*-month periods ended *March 31, 2026* and *2025*:

---

| | | |
|:---|:---|:---|
|  | ***Three Months Ended March 31,*** | ***Three Months Ended March 31,*** |
|  | ***2026*** | ***2025*** |
| Equipment purchases and de-install costs | $10000 | $1307000 |
| Costs incurred to maintain equipment | 248000 | 251000 |
| Total related party transactions | $258000 | $1558000 |

---

The Company also had commitments to purchase and install *two* Esprit units, and *two* LINACs, and to service the related equipment totaling $10,464,000 as of *March 31, 2026*.

Related party liabilities on the condensed consolidated balance sheets consist of the following as of *March 31, 2026* and *December 31, 2025*:

---

| | | |
|:---|:---|:---|
|  | ***March 31,*** | ***December 31,*** |
|  | ***2026*** | ***2025*** |
| Accounts payable, asset retirement obligation and other accrued liabilities | $2206000 | $1887000 |

---

**Item 2.**&nbsp;&nbsp;&nbsp;&nbsp;**Management**'**s Discussion and Analysis of Financial Condition and Results of Operations**

This quarterly report to the SEC may be deemed to contain certain forward-looking statements. The Private Securities Litigation Reform Act of 1995 has established that these statements qualify for safe harbors from liability. Forward-looking statements may include words like we "believe", "anticipate", "target", "expect", "pro forma", "estimate", "intend", "will", "is designed to", "plan" and words of similar meaning. Forward-looking statements describe our future plans, objectives, expectations or goals. Such statements address future events and conditions and include, but are not limited to, such things as capital expenditures, earnings, liquidity and capital resources, financing of our business, government programs and regulations, legislation affecting the health care industry, the expansion of our proton beam radiation therapy business, accounting matters, compliance with debt covenants, completed and potential acquisitions, competition, customer concentration, contractual obligations, timing of payments, technology and interest rates. These forward-looking statements involve known and unknown risks that may cause our actual results in future periods to differ materially from those expressed in any forward-looking statement. Factors that could cause or contribute to such differences include, but are not limited to, such things as our level of debt, the limited market for our capital-intensive services, the impact of lowered federal reimbursement rates, the impact of U.S. health care reform legislation, competition and alternatives to our services, technological advances and the risk of equipment obsolescence, our significant investment in the proton beam radiation therapy business, restrictions in our debt agreements that limit our flexibility to operate our business, our ability to repay our indebtedness, breaches in security of our information technology, and the small and relatively illiquid market for our stock. These lists are not all-inclusive because it is not possible to predict all factors. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the SEC, including the Annual Report on Form 10-K for the year ended December 31, 2025. Any forward-looking statement speaks only as of the date such statement was made, and we are not obligated to update any forward-looking statement to reflect events or circumstances after the date on which such statement was made, except as required by applicable laws or regulations.

<u>**Overview**</u>

American Shared Hospital Services is a leading provider of turn-key technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. The main drivers of the Company's revenue are numbers of sites, procedure volume, and reimbursement. The Company delivers radiation therapy through medical equipment leasing and direct patient services, its two reportable segments. The medical equipment leasing segment, which we also refer to as the Company's leasing segment, operates by fee-per-use contracts or revenue sharing contracts where the Company shares in the revenue and operating costs of the equipment. The Company leases seven Gamma Knife systems and one PBRT system as of March 31, 2026, where a contract exists between the hospital and the Company.

The Company acquired 60% of the equity interests of the RI Companies, which operate three single-unit radiation therapy facilities in Rhode Island. The Company, through GKF, owns and operates two single-unit Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. The Company also owns and operates a single-unit radiation therapy center in Puebla, Mexico. The Company's facilities in Rhode Island, Peru, Ecuador, and Mexico are considered direct patient services, where a contract exists between the Company's facilities and the individual treated at the facility.

Based on the guidance provided in accordance with ASC 280 *Segment Reporting*, the Company determined it has two reportable segments, leasing and direct patient services. See Note 1 - Basis of Presentation to the condensed consolidated financial statements for additional information. The Company's Management's Discussion and Analysis of Financial Condition and Results of Operations reflects activity for both segments and specifically addresses a segment when appropriate to the discussion.

<u>**Reimbursement**</u>

The Centers for Medicare and Medicaid ("CMS") has established a 2026 delivery code reimbursement rate of approximately $7,525 ($7,645 in 2025) for a Medicare Gamma Knife treatment. The approximate CMS reimbursement rates for delivery of PBRT for a simple treatment without compensation for 2026 is $565 ($578 in 2025) and $1,277 ($1,276 in 2025) for simple with compensation, intermediate and complex treatments, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12

------

<u>**Application of Critical Accounting Policies and Estimates**</u>

The Company's condensed consolidated financial statements are prepared in accordance with generally accepted accounting principles and follow general practices within the industry in which it operates. Application of these principles requires management to make estimates, assumptions and judgments that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. These estimates, assumptions and judgments are based on information available as of the date of the condensed consolidated financial statements; accordingly, as this information changes, the condensed consolidated financial statements could reflect different estimates, assumptions and judgments. Certain policies inherently have a greater reliance on the use of estimates, assumptions and judgments and as such have a greater possibility of producing results that could be materially different than originally reported.

The most significant accounting policies followed by the Company are presented in Note 2 to the consolidated financial statements in the Company's annual report on Form 10-K for the year ended December 31, 2025. These policies along with the disclosures presented in the other condensed consolidated financial statement notes and, in this discussion, and analysis, provide information on how significant assets and liabilities are valued in the condensed consolidated financial statements and how those values are determined. Based on the valuation techniques used and the sensitivity of financial statement amounts, and the methods, assumptions and estimates underlying those amounts, management has identified revenue recognition for revenue sharing arrangements, and the carrying value of property and equipment and useful lives, and as such the aforementioned could be most subject to revision as new information becomes available. The following are our critical accounting policies in which management's estimates, assumptions and judgments most directly and materially affect the condensed consolidated financial statements:

<u>**Revenue Recognition**</u>

The Company recognizes revenues under ASC 842 and ASC 606. The Company had seven domestic Gamma Knife units, two international Gamma Knife units, three domestic LINAC units, one international LINAC unit, and one PBRT system in operation in the United States as of March 31, 2026, and ten domestic Gamma Knife units, two international Gamma Knife units, three domestic LINAC units, and one PBRT system in operation in the United States as of March 31, 2025. Five of the Company's seven domestic Gamma Knife customers are under fee-per-use contracts, and two customers are under revenue sharing arrangements. The seven domestic Gamma Knife contracts operate under the Company's leasing segment. The Company's PBRT system at Orlando Health is considered a revenue share contract operating under the leasing segment. On March 13, 2026, the Company and Orlando Health, Inc. entered into an amendment to their PBRT lease agreement to, among other things, extend the term through April 5, 2033. The Company's interest in three single-unit radiation therapy facilities, acquired in Rhode Island in May 2024, and the Company's single-unit LINAC facility in Puebla, Mexico operate under the Company's direct patient services segment. The Company, through GKF, also owns and operates two single-unit, international Gamma Knife facilities in Lima, Peru and Guayaquil, Ecuador. These two units economically operate under the Company's direct patient services segment.

*Rental revenue from medical equipment leasing (*"*leasing*"*)* – The Company recognizes revenues under ASC 842 when services have been rendered and collectability is reasonably assured, on either a fee-per-use or revenue sharing basis. The terms of the contracts do not contain any guaranteed minimum payments. The Company's lease contracts typically have a ten-year term and are classified as either fee-per-use or revenue sharing. Fee-per-use revenues are recognized at the time the procedures are performed, based on each hospital's contracted rate and the number of procedures performed. Under revenue sharing arrangements, the Company receives a contracted percentage of the reimbursement received by the hospital. The amount the Company expects to receive is recorded as revenue and estimated based on historical experience. Revenue estimates are reviewed periodically and adjusted as necessary. Some of the Company's revenue sharing arrangements also have a cost sharing component. The Company records an estimate of operating costs which are reviewed on a regular basis and adjusted as necessary to more accurately reflect the actual operating costs. The operating costs are recorded as other direct operating costs in the condensed consolidated statements of operations. For the three-month period ended March 31, 2026, the Company recognized leasing revenue of approximately $3,020,000 compared to $2,991,000 for the same period in the prior year. For the three-month period ended March 31, 2026, $1,956,000 of the ASC 842 revenues were for PBRT services compared to $1,642,000, for the same period in the prior year.

*Direct patient services income* – The Company has stand-alone facilities in Lima, Peru, Guayaquil, Ecuador, and Puebla, Mexico where contracts exist between the Company's facilities and the individual patients treated at the facility. Under ASC 606, the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of a Gamma Knife or radiation therapy treatment. Revenue related to these treatments is recognized on a gross basis at the time when the patient receives treatment. There is no variable consideration present in the Company's performance obligation and the transaction price is agreed upon per the stated contractual rate. GKPeru's payment terms are typically prepaid for self-pay patients and insurance provider payments are paid net 30 days. GKCE's patient population is primarily covered by a government payor and payments are paid between three and six months following issuance of an invoice. The facility in Puebla currently has a contract with one local hospital to cover its eligible patient base and is also treating self-pay patients. Puebla's payment terms are typically prepaid for self-pay patients and net 30 days for the hospital patients. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 13

------

On May 7, 2024, the Company acquired 60% of the interests of the RI Companies. The RI Companies operate three, existing, stand-alone radiation therapy cancer centers in Woonsocket, Warwick and Providence, Rhode Island, where contracts exist between the Company's facilities and the individual patients treated at the facility. Under ASC 606, the Company acts as the principal in these transactions and provides, at a point in time, a single performance obligation, in the form of radiation therapy treatment. Revenue related to radiation therapy is recognized at the expected amount to be received, based on insurance contracts and payor mix, when the patient receives treatment. There is no variable consideration present in the Company's performance obligation and the transaction price is agreed upon per the stated contractual rate. Payment terms at these facilities are typically prepaid for self-pay patients and insurance providers are paid net 30 to 60 days. The Company did not capitalize any incremental costs related to the fulfillment of its customer contracts. The Company also concluded the three radiation therapy facilities are part of its direct patient services segment, see further discussion at Note 1 - Basis of Presentation to the condensed consolidated financial statements.

Accounts receivable balances under ASC 606 at March 31, 2026 and January 1, 2026 were $8,484,000 and $8,138,000, respectively. Accounts receivable balances under ASC 606 at March 31, 2025 and January 1, 2025 were $6,120,000 and $6,073,000, respectively. For the three-month periods ended March 31, 2026, the Company recognized direct patient services revenues of approximately $4,064,000 compared to $3,121,000 for the same period in the prior year.

**<u>Impairment of Long-lived Assets</u>**

The Company assesses the recoverability of its long-lived assets when events or changes in circumstances indicate their carrying value may not be recoverable. Such events or changes in circumstances may include: a significant adverse change in the extent or manner in which a long-lived asset is being used, significant adverse change in legal factors or in the business climate that could affect the value of a long-lived asset, an accumulation of costs significantly in excess of the amount originally expected for the acquisition or development of a long-lived asset, current or future operating or cash flow losses that demonstrate continuing losses associated with the use of a long-lived asset, or a current expectation that, more likely than not, a long-lived asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The Company performs impairment testing at the asset group level that represents the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities. The Company assesses recoverability of a long-lived asset by determining whether the carrying value of the asset group can be recovered through projected undiscounted cash flows over their remaining lives. If the carrying value of the asset group exceeds the forecasted undiscounted cash flows, an impairment loss is recognized, measured as the amount by which the carrying amount exceeds estimated fair value. An impairment loss is charged to the condensed consolidated statement of operations in the period in which management determines such impairment.

<u>**Accounting Pronouncements Issued and**</u> **<u>Adopted</u>** 

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2023-09 *Income Taxes (Topic 740) Improvements to Income Tax Disclosures* ("ASU 2023-09") which requires entities, on an annual basis, to disclose: specific categories in the rate reconciliation, additional information for reconciling items that meet a quantitative threshold, the amount of income taxes paid, net of refunds, disaggregated by jurisdiction, income or loss from continuing operations before income tax, income tax expense from continuing operations disaggregated between foreign and domestic, and income tax expense from continuing operations disaggregated by federal, state and foreign. ASU 2023-09 is effective for annual periods beginning after December 15, 2024, and interim reporting periods beginning after December 15, 2025. The Company adopted ASU 2023-09 for the year-ended December 31, 2025, prospectively, and enhanced its disclosure requirements, accordingly.

In July 2025, the FASB issued ASU 2025-05 *Measurement of Credit Losses for Accounts Receivable and Contract Assets* ("ASU 2025-05") which provides (1) all entities with a practical expedient and (2) entities other than public business entities, with an accounting policy election when estimating credit losses for current accounts receivable and current contract assets arising from transactions accounted for under Topic 606. ASU 2025-05 is effective for annual reporting periods beginning after December 15, 2025 and interim reporting periods within those annual reporting periods. Early adoption is permitted in both interim and annual reporting periods in which financial statements have not yet been issued or made available for issuance. The Company adopted ASU 2025-05 for the period-ended March 31, 2026 and concluded it did not have a material impact to its condensed consolidated financial statements.

<u>**Accounting Pronouncements Issued and** N**ot** Y</u>**<u>et Adopted</u>**

In November 2024, the FASB issued ASU 2024-03 *Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures* ("ASU 2024-03") which requires entities to 1. disclose amounts of (a) purchase of inventory, (b) employee compensation, (c) depreciation, (d) intangible asset amortization, and, (e) depreciation, depletion, and amortization recognized as part of oil-and gas-producing activities, 2. include certain amounts that are already required to be disclosed under current Generally Accepted Accounting Principles in the same disclosures as other disaggregation requirements, 3. disclose a qualitative description of the amounts remaining in relevant expense captions that are not necessarily disaggregated quantitatively, and 4. disclose the total amount of selling expenses, in annual reporting periods, an entity's definition of selling expense. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. The Company is currently evaluating ASU 2024-03 to determine the impact it may have on its consolidated financial statements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 14

------

<u>**First Quarter 2026 Results**</u>

Revenues increased by $972,000 to $7,084,000 for the three-month period ended March 31, 2026 compared to $6,112,000 for the same period in the prior year. Revenues from the Company's leasing segment increased by $29,000 to $3,020,000 for the three-month period ended March 31, 2026 compared to $2,991,000 for the same period in the prior year. The increase in leasing revenue was due to a higher number of Gamma Knife and PBRT procedures compared to the same period in the prior year. Revenues from the Company's direct patient services segment increased by $943,000 to $4,064,000 for the three-month period ended March 31, 2026 compared to $3,121,000 for the same period in the prior year. The increase in direct patient services revenue was due to a higher number of procedures at the RI facilities and the Company's radiation therapy facility in Puebla.

Radiation therapy revenues generated from the three stand-alone facilities acquired through the RI Acquisition and the radiation therapy facility in Puebla were $2,920,000 for the three-month period ended March 31, 2026, compared to $2,374,000 for the same period in the prior year. Radiation therapy procedures for the three stand-alone facilities acquired through the RI Acquisition and the radiation therapy facility in Puebla were 6,311 for the three-month period ended March 31, 2026, compared to 6,726 for the same period in the prior year.

Revenues generated from the Company's PBRT system increased by $314,000 to $1,956,000 for the three-month period ended March 31, 2026, compared to $1,642,000 for the same period in the prior year, respectively. The increase for the three-month period ended March 31, 2026, was driven by higher procedure volumes.

The number of PBRT fractions increased by 172 to 1,003 for the three-month period ended March 31, 2026 compared to 831 for the same period in the prior year. The increase in PBRT volumes for the three-month period ended March 31, 2026 was due to what the Company believes are normal, cyclical fluctuations.

Gamma Knife revenue increased by $112,000 to $2,208,000 for the three-month period ended March 31, 2026 compared to $2,096,000 for the same period in the prior year. The increase for the three-month period ended March 31, 2026 was due to increased procedure volume from the direct patient services segment, offset by lower procedure volume from the leasing segment.

The number of Gamma Knife procedures increased by 21 to 229 for the three-month period ended March 31, 2026 compared to 208 for the same period in the prior year. Gamma Knife procedures from the Company's leasing segment decreased 10.1% for the three-month period ended March 31, 2026 due to the expiration of one customer contract in April 2025. Gamma Knife procedures from the Company's direct patient services segment, which are the two international Gamma Knife locations, increased 44% for the three-month period ended March 31, 2026, compared to the same period in the prior year. The Company completed the equipment upgrade in Peru to a Gamma Knife Esprit in June 2025. Following the upgrade, there was an increase in volume driven by shorter treatment times. The Company's facility in Ecuador also experienced a 49% increase in volumes for the three-month period ended March 31, 2026 compared to same period in the prior year. The patient populations in Peru and Ecuador are primarily insured by local government therefore volumes can be impacted by local legislation changes or social and economic factors. Both facilities were impacted by local factors during the first quarter of 2025.

Total costs of revenue increased by $626,000 to $5,796,000 for the three-month period ended March 31, 2026 compared to $5,170,000 for the same period in the prior year.

Maintenance and supplies and other direct operating costs, related party, increased by $200,000 to $1,061,000 for the three-month period ended March 31, 2026 compared to $861,000 for the same period in the prior year. The increase in maintenance and supplies and other direct operating costs, related party, for the three-month period ended March 31, 2026, was due to maintenance for the LINAC in Puebla, Mexico that was previously under warranty, maintenance for the LINAC equipment in Rhode Island, and the PBRT maintenance contract, which increases on an annual basis.

Depreciation and amortization decreased by $156,000 to $1,289,000 for the three-month period ended March 31, 2026 compared to $1,445,000 for the same period in the prior year. The decrease in depreciation and amortization for the three-month period ended March 31, 2026 was due to the expiration of one Gamma Knife customer contract in April 2025, depreciation on the Gamma Knife equipment in Peru that was replaced during the second quarter of 2025, and assets in Rhode Island that became fully depreciated.

Other direct operating costs increased by $582,000 to $3,446,000 for the three-month period ended March 31, 2026 compared to $2,864,000 for the same period in the prior year. The increase in other direct operating costs for the three-month period ended March 31, 2026 was primarily due to operating costs at the RI facilities, which are part of the Company's direct patient services segment and have higher operating costs compared to facilities in the Company's leasing segment.

Selling and administrative expense increased by $102,000 to $1,910,000 for the three-month period ended March 31, 2026 compared to $1,808,000 for the same period in the prior year. The increase in selling and administrative expense for the three-month period ended March 31, 2026 was primarily due to audit, tax and consulting fees, offset by lower legal fees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 15

------

Interest expense decreased by $131,000 to $302,000 for the three-month period ended March 31, 2026 compared to $433,000 for the same period in the prior year. The decrease in interest expense for the three-month period ended March 31, 2026 was due to a lower average principal balance on the Company's debt compared to the same period in the prior year.

Interest and other income, net, decreased by $10,000 to $54,000 for the three-month period ended March 31, 2026 compared to $64,000 for the same period in the prior year. The decrease for the three-month period ended March 31, 2026 was due to lower interest income received on the Company's cash, driven primarily by lower average cash balances compared to the same period in the prior year.

Net loss attributable to non-controlling interests increased by $63,000 to a loss of $350,000 for the three-month period ended March 31, 2026 compared to $287,000 for the same period in the prior year. Net income or loss attributable to non-controlling interests represents net income or loss earned by the 40% non-controlling interest in the Rhode Island facilities, the 19% non-controlling interest in GKF, and net income or loss of the non-controlling interests in various subsidiaries controlled by GKF. The change in net income or loss attributable to non-controlling interests reflects the relative profitability of the three Rhode Island facilities and GKF and its subsidiaries.

Net loss attributable to American Shared Hospital Services decreased by $13,000 to a net loss of $612,000, or $0.09 per diluted share for the three-month period ended March 31, 2026 compared to a net loss of $625,000, or $0.10 per diluted share for the same period in the prior year. Net loss for the three-month period ended March 31, 2026 decreased primarily due to increased revenues compared to the same period in the prior year. The Company incurred a net loss for three-month period ended March 31, 2026, due to losses incurred by the direct patient services segments, driven by higher operating costs for these facilities.

**Liquidity and Capital Resources**

The Company's primary liquidity needs are to fund capital expenditures as well as support working capital requirements. In general, the Company's principal sources of liquidity are cash and cash equivalents on hand. The Company had cash, cash equivalents and restricted cash of $5,223,000 at March 31, 2026 compared to $3,712,000 at December 31, 2025. The Company's cash position increased by $1,511,000 during the first three months of 2026 driven by cash provided by operating activities of $2,149,000. This increase was offset by payment for the purchase of property and equipment of $41,000, payments on long-term debt of $472,000, and distributions to non-controlling interests of $125,000. The Company's expected primary cash needs on both a short and long-term basis are for capital expenditures, business expansion, working capital, and other general corporate purposes. The Company has scheduled interest and principal payments under its debt obligations of approximately $10,407,000 during the next 12 months. Of this amount, there was an aggregate of $7,605,000 due on April 9, 2026 for the Term Loan and DDTL. For a further discussion of these obligations, see "Long-Term Debt" below.

**Working Capital**

The Company had a working capital deficit at March 31, 2026 of $5,446,000 compared to a working capital deficit of $5,724,000 at December 31, 2025. The $278,000 decrease in working capital deficit was primarily due to increasing cash and a decrease in the current portion of long-term debt, net, offset in part by an increase in accounts payable and related party payables. If the Company is unable to negotiate an extension to the Credit Agreement, the Company's liquidity will be adversely impacted and the Company's ability to satisfy all of its commitments over the next twelve months in accordance with their current terms would be jeopardized. See additional discussion in the "Long-Term Debt" and "Commitments" sections below. The Company, in the past, has secured financing for its Gamma Knife and radiation therapy units. The Company has secured financing for its projects from several lenders and anticipates that it will be able to secure financing on future projects from these or other lending sources, but there can be no assurance that financing will continue to be available on acceptable terms. Furthermore, if the Company's payment obligations under the Credit Agreements become accelerated due to the events of default under such agreements, the Company would not have sufficient cash on hand, cash flow from operations, and other cash resources to satisfy such accelerated payment obligations, which raises substantial doubt about the Company's ability to continue as a going concern. See additional discussion in the "Long-Term Debt" and "Going-Concern Consideration" sections below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 16

------

**Long-Term Debt**

On April 9, 2021, the Company along with certain of its domestic subsidiaries (collectively, the "Loan Parties") entered into a five year $22,000,000 credit agreement (the "Credit Agreement") with Fifth Third Bank, N.A. ("Fifth Third"). The Credit Agreement includes three loan facilities. The first loan facility is a $9,500,000 term loan (the "Term Loan") which was used to refinance the domestic Gamma Knife debt and finance leases, and associated closing costs. The second loan facility of $5,500,000 is a delayed draw term loan (the "DDTL") which was used to refinance the Company's PBRT finance leases and associated closing costs, as well as to provide additional working capital. The third loan facility provides for a $7,000,000 revolving line of credit (the "Revolving Line") available for future projects and general corporate purposes. The facilities have a five-year maturity, which matured on April 9, 2026, and carry a floating interest rate based on the Secured Overnight Financing Rate ("SOFR") plus 3.0% (6.86% as of March 31, 2026) and are secured by a lien on substantially all of the assets of the Loan Parties and guaranteed by ASHS, Orlando and ASRS. There was $7,075,000 due on April 9, 2026 for the Term Loan and DDTL.

On January 25, 2024 (the "First Amendment Effective Date"), the Company and Fifth Third entered into a First Amendment to Credit Agreement (the "First Amendment"), which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $2,700,000 (the "Supplemental Term Loan"). The proceeds of the Supplemental Term Loan were advanced in a single borrowing on January 25, 2024, and were used for capital expenditures related to the Company's operations in Puebla, Mexico and other related transaction costs. The Supplemental Term Loan will mature on January 25, 2030 (the "Maturity Date"). Interest on the Supplemental Term Loan was payable monthly during the initial twelve month period following the First Amendment Effective Date. Following that twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Supplemental Term Loan by the Maturity Date. The Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

On December 18, 2024 (the "Second Amendment Effective Date"), the Company and Fifth Third entered into a Second Amendment to the Credit Agreement (the "Second Amendment"), which amended the Credit Agreement to add a new term loan in the aggregate principal amount of $7,000,000 (the "Second Supplemental Term Loan"). The proceeds of the Second Supplemental Term Loan were advanced in a single borrowing on December 18, 2024, and were used for capital expenditures related to the Company's domestic Gamma Knife leasing operations and the RI Acquisition and related transaction costs. The Second Supplemental Term Loan will mature on December 18, 2029 (the "Second Maturity Date"). Interest on the Second Supplemental Term Loan is payable monthly during the initial twelve month period following the Second Amendment Effective Date. Following such twelve month period, the Company is required to make equal monthly payments of principal and interest to fully amortize the amount outstanding under the Second Supplemental Term Loan over a period of seven years. All unpaid principal of the Second Supplemental Term Loan and accrued and unpaid interest thereon is due and payable in full on the Second Maturity Date. The Second Supplemental Term Loan is secured by a lien on substantially all of the assets of the Company and certain of its domestic subsidiaries. Pursuant to the First Amendment, advances under the Credit Agreement bear interest at a floating rate per annum equal to SOFR plus 3.00%, subject to a SOFR floor of 0.00%.

The long-term debt on the condensed consolidated balance sheets related to the Term Loan, DDTL, Revolving Line, Supplemental Term Loan and Second Supplemental Term Loan was $15,895,000 and $16,197,000 as of March 31, 2026 and December 31, 2025, respectively. The Company did not capitalize any debt issuance as of March 31, 2026 and December 31, 2025, related to the issuance of the Supplemental Term Loan and Second Supplemental Term Loan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The Credit Agreement contains customary covenants and representations, including without limitation, a minimum fixed charge coverage ratio of 1.25 and maximum funded debt to EBITDA ratio of 3.0 to 1.0 (tested on a trailing twelve-month basis at the end of each fiscal quarter), an obligation that the Company maintain $5,000,000 of unrestricted cash, reporting obligations, limitations on dispositions, changes in ownership, mergers and acquisitions, indebtedness, encumbrances, distributions, investments, transactions with affiliates and capital expenditures.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; On September 30, 2025, the Company received a limited waiver from Fifth Third with respect to its failure to be in compliance with the maximum funded debt to EBITDA ratio covenant in the Credit Agreement as of June 30, 2025 and with respect to the delivery of items following the closing of the Second Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As previously disclosed, (i) on December 10, 2025, the Loan Parties received notice from Fifth Third asserting that an Event of Default had occurred under the Credit Agreement due to the Borrowers' failure to comply with the Minimum Cash Covenant as of September 30, 2025, and (ii) as of December 31, 2025, the Company was not in compliance with the minimum fixed-charge coverage ratio, the maximum funded debt-to-EBITDA ratio, and the Minimum Cash Covenant required by the Credit Agreement and notified Fifth Third of such non-compliance (all such defaults in clauses (i) and (ii), collectively, the "Financial Covenant Defaults"). The Financial Covenant Defaults under the Credit Agreement remain uncured as of March 31, 2026, and, as a result, the Loan Parties are not in compliance with the Credit Agreement as of such date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Due to the Financial Covenant Defaults described above, Fifth Third may exercise any of its rights, powers, privileges, and remedies under the Credit Agreement, the other Loan Documents, and applicable law, including the right to accelerate the Borrowers' payment obligations under the Credit Agreement. In December 2025, as a result of the Financial Covenant Defaults, Fifth Third notified the Company that, among other things, it had suspended the Revolving Loan Commitment with respect to additional Revolving Loan Advances. To date, Fifth Third has not accelerated the obligations of the Loan Parties under the Credit Agreement or other Loan Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; As noted above, the Credit Agreement matured on April 9, 2026 and is secured by a lien on substantially all of the assets of the Loan Parties and is guaranteed by ASHS. The Loan Parties did not satisfy all outstanding obligations under the Credit Agreement on the maturity date. ASHS is currently in discussions with Fifth Third regarding a waiver and an amendment to extend the maturity date of the Credit Agreement. However, there can be no assurances regarding the outcome of such discussions.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The loan entered into with United States International Development Finance Corporation ("DFC") in connection with the acquisition of GKCE in June 2020 (the "DFC Loan") was obtained through the Company's wholly-owned subsidiary, HoldCo and is guaranteed by GKF. The DFC Loan is secured by a lien on GKCE's assets. The first tranche of the DFC Loan was funded in June 2020. During the fourth quarter of 2023, the second tranche of the DFC loan was funded to finance the equipment upgrade in Ecuador. The amount outstanding under the first tranche of the DFC Loan is payable in 29 quarterly installments with a fixed interest rate of 3.67%. The amount outstanding under the second tranche of the DFC Loan is payable in 16 quarterly installments with a fixed interest rate of 7.49%. The long-term debt on the condensed consolidated balance sheets related to the DFC Loan was $985,000 and $1,149,000 as of March 31, 2026 and December 31, 2025, respectively.

The DFC Loan contains customary covenants including without limitation, requirements that HoldCo maintain certain financial ratios related to liquidity and cash flow as well as depository requirements. On March 28, 2024, HoldCo received a waiver and amendment from DFC for certain covenants as of December 31, 2023 and through December 31, 2024 and amended other covenants and definitions permanently. On March 3, 2025, the Company received an additional waiver from DFC for certain covenants as of December 31, 2024 and through December 31, 2025. HoldCo was not in compliance with the cash to debt covenant at March 31, 2026. The Company notified DFC of this non-compliance and is in discussions for an extended waiver or amendment to the DFC Loan. However, there can be no assurances regarding the outcome of such discussions.

As a result of the Loan Parties' Financial Covenant Defaults under the Credit Agreement with Fifth Third discussed above, ASHS determined that the non-compliance with the Credit Agreement could be deemed to have resulted in an Event of Default (as defined in the DFC Loan) under the DFC Loan. However, as of the date of this Quarterly Report, DFC has not delivered any notice to HoldCo or ASHS asserting the occurrence of an Event of Default resulting from the Financial Covenant Defaults or sought to exercise any remedies it may have under the DFC Loan as a result thereof.

Furthermore, ASHS has determined that HoldCo's non-compliance with the DFC Loan could be deemed to have resulted in an Event of Default (as defined in the Credit Agreement) under the Credit Agreement with Fifth Third. However, as of the date of this Quarterly Report, Fifth Third has not delivered any notice to the Loan Parties asserting that such an Event of Default has occurred or sought to exercise any remedies it may have under the Credit Agreement as a result thereof.

The Company's failure to comply with the covenants under the Credit Agreements could result in the Company's credit commitments being terminated and the principal of any outstanding borrowings, together with any accrued but unpaid interest, under the Credit Agreements could be declared immediately due and payable. Furthermore, the lenders under the Credit Agreements could also exercise their rights to take possession of, and to dispose of, the collateral securing the credit facilities and loans and could pursue additional default remedies upon default as set forth in each such agreement.

As long as the Company remains in default under the Credit Agreements, Fifth Third and DFC could accelerate all payment obligations under the Credit Agreements. If Fifth Third or DFC were to accelerate all payment obligations under the Credit Agreements as a result of the defaults thereunder, the Company would not have sufficient cash on hand to satisfy such accelerated payment obligations. As a result, these conditions raise substantial doubt about the Company's ability to continue as a going concern.

In November and December 2024, GKCE obtained two loans with banks locally in Ecuador (the "GKCE Loans"). The GKCE Loans carry interest rates of 12.60% and 12.78% and are payable in twelve and thirty-six equal monthly installments of principal and interest, respectively. The Company did not capitalize any debt issuance costs related to the GKCE Loans. Total long-term debt on the condensed consolidated balance sheets related to the GKCE Loans was $47,000 and $53,000 as of March 31, 2026 and December 31, 2025, respectively.

As of March 31, 2026, long-term debt on the condensed consolidated balance sheets was $16,843,000. See Note 3 - Long Term Debt to the condensed consolidated financial statements for additional information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 17

------

**Commitments**

As of March 31, 2026, the Company had commitments to purchase and install two Esprit and two LINAC systems. The Esprit upgrades and one LINAC installation are anticipated to occur in the second half of 2026 or later at existing customer sites. The remaining LINAC is reserved for a future customer site. Total Gamma Knife and LINAC commitments as of March 31, 2026 were $7,884,000. There are no deposits on the condensed consolidated balance sheets related to these commitments as of March 31, 2026, nor are there any penalties if the Company decides to not execute these commitments. The Company's current intent is to finance substantially all of these commitments. There can be no assurance that financing will be available for the Company's initiatives or future projects, or at terms that are acceptable to the Company. However, the Company currently has cash on hand of $5,223,000 and is actively engaged with financing resources to fund these projects.

As of March 31, 2026, the Company had commitments to service and maintain its Gamma Knife, LINAC, and PBRT equipment. The service commitments are carried out via contracts with Mevion, Elekta, Solutech and Mobius Imaging, LLC. The Company's commitment to purchase one LINAC system also includes a 5-year agreement to service the equipment, respectively. Total service commitments as of March 31, 2026 were $5,705,000. The Gamma Knife and certain other service contracts are paid monthly, as service is performed. The Company believes that cash flow from cash on hand and operations will be sufficient to cover these payments.

**Related Party Transactions** 

The Company's Gamma Knife business is operated through its 81% indirect interest in its GKF subsidiary. The remaining 19% of GKF is owned by a wholly owned U.S. subsidiary of Elekta, which is the manufacturer of the Gamma Knife. Since the Company purchases its Gamma Knife units from Elekta, there are significant related party transactions with Elekta, such as equipment purchases, commitments to purchase and service equipment, and costs to maintain the equipment.

The following table summarizes related party activity for the three-month periods ended March 31, 2026 and 2025:

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Equipment purchases and de-install costs | $10000 | $1307000 |
| Costs incurred to maintain equipment | 248000 | 251000 |
| Total related party transactions | $258000 | $1558000 |

---

The Company also had commitments to purchase and install two Esprit units and two LINACs, and service the related equipment totaling $10,464,000 as of March 31, 2026.

Related party liabilities on the condensed consolidated balance sheets consist of the following as of March 31, 2026 and December 31, 2025

---

| | | |
|:---|:---|:---|
|  | **March 31,** | **December 31,** |
|  | **2026** | **2025** |
| Accounts payable, asset retirement obligation and other accrued liabilities | $2206000 | $1887000 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18

------

**Item 3.**&nbsp;&nbsp;&nbsp;&nbsp;**Quantitative and Qualitative Disclosures about Market Risk**

The Company does not hold or issue derivative instruments for trading purposes and is not a party to any instruments with leverage or prepayment features. The Company does not have affiliation with partnerships, trusts or other entities whose purpose is to facilitate off-balance sheet financial transactions or similar arrangements**,** and therefore has no exposure to the financing, liquidity, market or credit risks associated with such entities. At March 31, 2026, the Company had no significant long-term, market-sensitive investments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 19

------

**Item 4.**&nbsp;&nbsp;&nbsp;&nbsp;**Controls and Procedures**

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934. These controls and procedures are designed to ensure that material information relating to the Company and its subsidiaries is communicated to the principal executive officer and our principal financial officer. Based on that evaluation, our principal executive officer and our principal financial officer concluded that, as of March 31, 2026, our disclosure controls and procedures were not effective due to the material weakness in our internal controls over financial reporting described in our Annual Report on Form 10-K for the year ended December 31, 2025, with respect to the Company having an insufficient number of personnel and resources with experience to create a proper control environment.

Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Securities Exchange Act of 1934 is accumulated and communicated to the issuer's management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

The Company's remediation plan related to the material weakness in our internal controls identified are to hire sufficient personnel with accounting and financial reporting experience to augment its current staff and to improve the timeliness of our overall effectiveness of the Company's closing and financial reporting processes, including as described in this paragraph. As previously disclosed, on December 19, 2024, the Company appointed a new Chief Financial Officer who also serves as the Company's principal financial officer and principal accounting officer and has extensive experience and expertise in billing and collections for radiation therapy facilities. During 2024, the Company outsourced its billing cycle for its Rhode Island facilities. In May 2025, the Company hired a Director of Revenue Cycle Management and effective June 1, 2025 began preparing to process the Rhode Island revenue cycle internally. Two additional staff members were hired during 2025 to support this process internally as well. While this process is still relatively new and continuing to be implemented, the Company expects this change to provide more control and efficiency to this process overall. Also, the Company hired an Accounting Manager on a full-time basis in late March 2025 in addition to using third party accounting consulting services as needed on an ongoing basis. The Company will continue to assess the need for additional resources, especially in the finance and accounting areas, as the Company's business continues to grow and expand.

The primary element of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects. As management continues to evaluate and work to improve our internal control over financial reporting, management may determine it is necessary to take additional measures to address the material weakness.

Except for the continued implementation of the remediation plan described above, there were no other changes in our internal control over financial reporting during the three-month period ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 20

------

**PART II - OTHER INFORMATION**

**Item 1.**&nbsp;&nbsp;&nbsp;&nbsp;**Legal Proceedings.**

None.

**Item 1A.**&nbsp;&nbsp;&nbsp;&nbsp;**Risk Factors**

There were no material changes during the period covered in this report to the risk factors previously disclosed in Part 1, Item 1A, of the Company's Annual Report on Form 10-K for the year ended December 31, 2025.

**Item 2.**&nbsp;&nbsp;&nbsp;&nbsp;**Unregistered Sales of Equity Securities and Use of Proceeds.**

None.

**Item 3.**&nbsp;&nbsp;&nbsp;&nbsp;**Defaults Upon Senior Securities.**

As described in Item 2 of Part I of this Quarterly Report under the subheading "Long-Term Debt", ASHS and certain of its subsidiaries are not in compliance with certain covenants under the Credit Agreements as of March 31, 2026. Additionally, the Loan Parties did not satisfy all outstanding obligations under the Credit Agreement with Fifth Third when it matured on April 9, 2026. To date, neither Fifth Third nor DFC have accelerated the obligations under the Credit Agreements. ASHS is currently in discussions with Fifth Third regarding an amendment to extend the maturity date of the Credit Agreement. However, there can be no assurances regarding the outcome of such discussions.

**Item 4.**&nbsp;&nbsp;&nbsp;&nbsp;**Mine Safety Disclosures**

Not applicable.

**Item *5.***&nbsp;&nbsp;&nbsp;&nbsp;**Other Information.**

During the *three*-month period ended *March 31, 2026*, none of the Company's directors or officers adopted, modified, or terminated a "Rule *10b5*-*1* trading arrangement" or a "non-Rule *10b5*-*1* trading arrangement," as those terms are defined in Item *408*(a) of Regulation S-K

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 21

------

**Item 6.**&nbsp;&nbsp;&nbsp;&nbsp;**Exhibit Index**

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  |  |  | Incorporated by reference herein | Incorporated by reference herein | Incorporated by reference herein |
| Exhibit Number |  | Description | Form | Exhibit | Date of Filing |
| 10.1 | ǂ | [Amendment Two to Proton Beam Radiation Therapy Lease Agreement effective as of March 13, 2026, by and between American Shared Hospital Services and Orlando Health, Inc.](http://www.sec.gov/Archives/edgar/data/744825/000143774926008996/ex_934968.htm) | 8-K 001-08789 | 10.1 | March 19, 2026 |
| 31.1 | \* | [Certification of Principal Executive Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex_942874.htm) |  |  |  |
| 31.2 | \* | [Certification of Principal Financial Officer pursuant to Rule 13a-14a/15d-14a, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002](ex_942875.htm) |  |  |  |
| 32.1 | \*\* | [Certifications of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002](ex_942876.htm) |  |  |  |
| 101.INS | \* | Inline XBRL Instance Document |  |  |  |
| 101.SCH | \* | Inline XBRL Taxonomy Extension Schema Document |  |  |  |
| 101.CAL | \* | Inline XBRL Taxonomy Calculation Linkbase Document |  |  |  |
| 101.DEF | \* | Inline XBRL Taxonomy Definition Linkbase Document |  |  |  |
| 101.LAB | \* | Inline XBRL Taxonomy Label Linkbase Document |  |  |  |
| 101.PRE | \* | Inline XBRL Taxonomy Extension Presentation Linkbase Document |  |  |  |
| 104 | \* | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline Instance XBRL contained in Exhibit 101 |  |  |  |
|  | \* | Filed herewith. |  |  |  |
|  | \*\* | Furnished herewith. |  |  |  |
|  | ǂ | *Certain portions of this exhibit have been omitted because they are not material, would be competitively harmful if publicly disclosed, and are of the type that the registrant treats as private or confidential.* |  |  |  |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 22

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

AMERICAN SHARED HOSPITAL SERVICES

Registrant

---

| | | |
|:---|:---|:---|
| Date: | May 14, 2026 | /s/ Raymond C. Stachowiak |
| | | Raymond C. Stachowiak |
| | | Executive Chairman of the Board (principal executive officer) |
| Date: | May 14, 2026 | /s/ Raymond S. Frech |
| | | Raymond S. Frech |
| | | Chief Financial Officer (principal financial and principal accounting officer) |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 23

## Exhibit 31.1

**Exhibit 31.1**

CERTIFICATION

I, Raymond C. Stachowiak, as executive chairman of the board of American Shared Hospital Services, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Shared Hospital Services;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 14, 2026

<u>/s/ Raymond C. Stachowiak</u>

Raymond C. Stachowiak

Executive Chairman of the Board (principal executive officer)

## Exhibit 31.2

**Exhibit 31.2**

CERTIFICATION

I, Raymond S. Frech, as chief financial officer of American Shared Hospital Services, certify that:

1. I have reviewed this quarterly report on Form 10-Q of American Shared Hospital Services;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| |
|:---|
| May 14, 2026 |
| /s/ Raymond S. Frech |
| Raymond S. Frech |
| Chief Financial Officer (principal financial officer and principal accounting officer) |

---

## Exhibit 32.1

**Exhibit 32.1**

CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

The certification set forth below is being submitted in connection with the Quarterly Report on Form 10-Q of American Shared Hospital Services for the quarterly period ended March 31, 2026 (the "Report") for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the "Exchange Act") and Section 1350 of Chapter 63 of Title 18 of the United States Code.

Ray Stachowiak, the Executive Chairman of the Board and Raymond S. Frech, the Chief Financial Officer of American Shared Hospital Services, each certifies that, to the best of his knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of American Shared Hospital Services.

May 14, 2026

---

| |
|:---|
| /s/ Raymond C. Stachowiak |
| Raymond C. Stachowiak |
| Executive Chairman of the Board (principal executive officer) |
| /s/ Raymond S. Frech |
| Raymond S. Frech |
| Chief Financial Officer (principal financial officer) |

---